A meta-analysis reveals that people with a poor heart failure prognosis stand to gain the most from sodium-glucose cotransporter SGLT2 inhibition, regardless of whether or not they have type 2 diabetes.
The proportion of individuals receiving second-line therapy for diabetes has decreased over time despite worsening glycemic control over the same period, US study findings indicate.
Real-world data confirm glycated hemoglobin and weight benefits, albeit attenuated, for people with type 2 diabetes switching to injectable semaglutide from other GLP-1 receptor agonists.
An extended-wear insulin infusion set, worn for up to 7 days, is more satisfactory to users than standard insulin infusion sets and does not adversely affect glycemic control, shows a study in people with type 1 diabetes.
People with type 2 diabetes who have mental health conditions are just as likely as those who do not to achieve their blood glucose targets, report researchers.
The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.
Being in a minority ethnic group and having low socioeconomic status increase women’s risk for developing certain long-term health complications after a pregnancy affected by gestational diabetes, a study shows.
The proven cardiovascular benefits of SGLT2 inhibitors has not led doctors to prioritize their use in people at high risk, show findings from UK general practice.
People with type 1 diabetes and poor glycemic control benefit from use of intermittently scanned continuous glucose monitoring versus self-monitored blood glucose, report the Flash UK investigators.
Increased team-based continuity of care correlates with decreased risk for cardiovascular disease in people with type 2 diabetes, researchers report in Diabetes Care.
Moderate- or high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin are the most effective statins for reducing non-high-density lipoprotein cholesterol levels in people with diabetes, study findings indicate.
Less than a third of nursing home residents who meet the criteria for overtreatment of type 2 diabetes have their treatment deintensified, suggests an analysis of Veterans Affairs data.
Two large cohort studies have demonstrated an increased likelihood of being diagnosed with type 2 diabetes in the months following SARS-CoV-2 infection.
Individuals with type 1 diabetes and residual β-cell function have better nocturnal and postprandial glycemic control than those with no β-cell function, UK study findings indicate.
Type 2 diabetes in young, lean people is much more common in Asian Indians than in White Europeans, say researchers who found that genetically determined beta-cell function may be to blame.
The gain or loss of more than 5% bodyweight within a 2-year period is associated with an increased risk for major adverse cardiovascular events in people with type 2 diabetes, say researchers.
Subcutaneous mini-dose glucagon reverses hypoglycemia more effectively than oral glucose tablets and helps adults with type 1 diabetes complete Ramadan fasts, shows a randomized crossover trial.